Publication:
Effect of harmane on mononeuropathic pain in rats

Simple item page
dc.contributor.authorARICIOĞLU, FEYZA
dc.contributor.authorsAricioglu, F; Korcegez, E; Ozyalcin, S
dc.contributor.editorPiletz, JE
dc.contributor.editorRegunathan, S
dc.contributor.editorErnsberger, P
dc.date.accessioned2022-03-12T15:58:52Z
dc.date.accessioned2026-01-11T13:22:06Z
dc.date.available2022-03-12T15:58:52Z
dc.date.issued2003
dc.description.abstractThis study was designed to investigate the effect of the endogenous beta-carboline, harmane, on neuropathic pain produced by chronic constriction injury (CCI) of the sciatic nerve. Thermal allodynia evaluations were made preoperatively, postoperatively on the fifteenth day, and after harmane administration. Harmane (1, 2.5, 5, 10, or 20 mg/kg) was administered intraperitoneally for 5 days beginning from postoperative day 15. Treatment with harmane had a profound anti-allodynic effect in a dose-dependent manner. In conclusion, harmane might provide a new approach to treatment of neuropathic pain.
dc.identifier.doi10.1196/annals.1304.021
dc.identifier.isbn1-57331-498-6
dc.identifier.issn0077-8923
dc.identifier.pubmed15028585
dc.identifier.urihttps://hdl.handle.net/11424/224194
dc.identifier.wosWOS:000189443800021
dc.language.isoeng
dc.publisherNEW YORK ACAD SCIENCES
dc.relation.ispartofAGMATINE AND IMIDAZOLINES: THEIR NOVEL RECEPTORS AND ENZYMES
dc.relation.ispartofseriesAnnals of the New York Academy of Sciences
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectharmane
dc.subjectchronic constriction injury
dc.subjectimidazoline
dc.subjectallodynia
dc.subjectRECEPTOR AGONIST
dc.subjectMOXONIDINE
dc.titleEffect of harmane on mononeuropathic pain in rats
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage184
oaire.citation.startPage180
oaire.citation.titleAGMATINE AND IMIDAZOLINES: THEIR NOVEL RECEPTORS AND ENZYMES
oaire.citation.volume1009

Files

Collections

Araştırma Çıktıları